Are we underestimating the benefits of lipid-lowering therapies? - PubMed
4 hours ago
- #LDL cholesterol
- #lipid-lowering
- #cardiovascular disease
- Cardiovascular disease is the leading cause of mortality worldwide, with LDL-C being a key target for preventing ASCVD.
- Available drugs (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) effectively reduce cardiovascular event risks.
- New oral therapies, including oral PCSK9 inhibitors and CETP inhibitors, are under investigation for enhanced treatment options.
- Cumulative LDL-C exposure impacts lifelong ASCVD risk; early intervention is crucial but implementation is often inadequate.
- Treatment gaps remain due to poor prescribing, adherence, and underutilization of lipid-lowering strategies in practice.
- Additional factors like lipoprotein(a), triglycerides, and inflammation require consideration for personalized prevention approaches.